Coherus Biosciences Inc (CHRS) Given Average Rating of “Buy” by Analysts

Shares of Coherus Biosciences Inc (NASDAQ:CHRS) have been assigned an average rating of “Buy” from the eleven ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $32.00.

A number of research firms have recently weighed in on CHRS. BidaskClub raised Coherus Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Zacks Investment Research lowered Coherus Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. ValuEngine raised Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Citigroup reissued a “buy” rating and set a $23.00 price objective on shares of Coherus Biosciences in a research note on Tuesday, November 7th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $17.00 price objective (down previously from $24.00) on shares of Coherus Biosciences in a research note on Wednesday, September 27th.

Shares of Coherus Biosciences (NASDAQ CHRS) traded down $0.65 on Friday, reaching $10.75. The company’s stock had a trading volume of 1,207,945 shares, compared to its average volume of 668,508. The stock has a market capitalization of $660.58, a price-to-earnings ratio of -1.98 and a beta of 3.89. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.46 and a current ratio of 5.46. Coherus Biosciences has a 1-year low of $8.05 and a 1-year high of $28.60.

Coherus Biosciences (NASDAQ:CHRS) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. equities research analysts anticipate that Coherus Biosciences will post -4.39 EPS for the current year.

Several large investors have recently added to or reduced their stakes in CHRS. SG Americas Securities LLC raised its holdings in shares of Coherus Biosciences by 32.7% during the second quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 1,785 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Coherus Biosciences by 12.6% during the second quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 1,046 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Coherus Biosciences by 497.4% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 10,491 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Coherus Biosciences during the second quarter valued at approximately $185,000. Finally, Bank of Montreal Can bought a new position in shares of Coherus Biosciences during the fourth quarter valued at approximately $135,000. 81.00% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/20/coherus-biosciences-inc-chrs-given-average-rating-of-buy-by-analysts.html.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply